The Role of Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor (AT1-AA) in Pathophysiology of Preeclampsia

Author(s): Nathan Campbell, Babbette LaMarca*, Mark W. Cunningham Jr.

Journal Name: Current Pharmaceutical Biotechnology

Volume 19 , Issue 10 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Preeclampsia is the leading cause of death and morbidity worldwide for the mother and fetus during pregnancy. Preeclampsia does not only affect the mother and the baby during pregnancy, but can also have long-term effects, such as the increased risk of hypertension and cardiovascular disease on the offspring and the postpartum mother later in life. The exact cause of preeclampsia is unknown, but women with preeclampsia have elevated concentrations of agonistic autoantibodies against the angiotensin II type 1 receptor (AT1-AA). These AT1-AA’s through multiple studies have shown to play a significant role in the pathology and possible genesis of preeclampsia. This review will discuss the discovery of AT1-AAs and the role of AT1-AAs in the pathophysiology of preeclampsia. This review will also discuss future therapeutic approaches towards the AT1-AA to prevent adverse pregnancy outcomes. Furthermore, we will examine the relationship between AT1-AA induced hypertension associated with increased oxidative stress, antiangiogenic factors (such as soluble fms-related tyrosine kinase-1 (sFlt-1), endothelin-1 (ET-1), inflammation, endothelial dysfunction, and reduced renal function. Understanding the pathological role of AT1-AAs in hypertensive pregnancies is important as we search for novel therapies to manage preeclampsia.

Keywords: Preeclampsia, angiotensin II type 1 receptor autoantibody (AT1-AA), oxidative stress, renal function, endothelin.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [781 - 785]
Pages: 5
DOI: 10.2174/1389201019666180925121254
Price: $65

Article Metrics

PDF: 26